A Comprehensive Analysis of the Stability of Blood Eosinophil Levels

Rationale: Blood eosinophil counts are used to inform diagnosis/management of eosinophilic asthma. Objectives: Examine blood eosinophil variability and identify factors affecting eosinophil levels to inform clinical interpretation. Methods: Post hoc analysis to understand eosinophil variability using data from four randomized controlled asthma trials. We examined 1) influence of intrinsic/extrinsic factors (comorbidities, medication, and patient history) using baseline data (n = 2,612); 2) monthly variation using placebo-treated patient data (n = 713); 3) stability of eosinophil classification (<150, 150–299, and ⩾300 cells/μl) in placebo-treated patients with monthly measurements over a 1-year period (n = 751); and 4) impact of technical factors (laboratory-to-laboratory differences and time from collection to analysis). Results: Of intrinsic/extrinsic factors examined, nasal polyps increased eosinophil levels by 38%, whereas current smoking decreased levels by 23%. Substantial seasonal differences in eosinophil counts were observed, with differences of ∼20% between July and January. Eosinophil levels between 150 and 299 cells/μl were least stable, with 44% of patients remaining in the same classification for seven of 10 measurements versus 59% and 66% of patients in the <150 and ⩾300 cells/μl subgroups, respectively. Measurements at different laboratories showed high association (Spearman’s correlation coefficient, R = 0.89); however, eosinophil counts were reduced, with longer time from collection to analysis, and variability increased with increasing eosinophil counts. Conclusions: Several intrinsic, extrinsic, and technical factors may influence, and should be considered in, clinical interpretation of eosinophil counts. Additionally, a single measurement may not be sufficient when using eosinophil counts for diagnosis/management of eosinophilic asthma.

[1]  T. Kawaguchi,et al.  Correlation between eosinophil count, its genetic background and body mass index: The Nagahama Study. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[2]  I. Pavord,et al.  Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations , 2019, Clinical and Translational Allergy.

[3]  Jianbo Shi,et al.  Concordant systemic and local eosinophilia relates to poorer disease control in patients with nasal polyps , 2019, The World Allergy Organization journal.

[4]  F. Albers,et al.  Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis , 2019, Respiratory Research.

[5]  S. Szefler,et al.  Seasonal variation in asthma exacerbations in the AUSTRI and VESTRI studies , 2019, ERJ Open Research.

[6]  M. A. Curotto de Lafaille,et al.  Variability of blood eosinophils in patients in a clinic for severe asthma , 2019, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[8]  P. Sfriso,et al.  Blood Eosinophil and Basophil Values Before and After Surgery for Eosinophilic-type Sinonasal Polyps , 2018, American journal of rhinology & allergy.

[9]  Sung-Dong Kim,et al.  Samter’s Triad: State of the Art , 2018, Clinical and experimental otorhinolaryngology.

[10]  É. Drumez,et al.  Virus-triggered exacerbation in allergic asthmatic children: neutrophilic airway inflammation and alteration of virus sensors characterize a subgroup of patients , 2017, Respiratory Research.

[11]  C. Perronne,et al.  Changes in eosinophil count during bacterial infection: revisiting an old marker to assess the efficacy of antimicrobial therapy. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[12]  R. Rennenberg,et al.  Within-day biological variation and hour-to-hour reference change values for hematological parameters , 2017, Clinical chemistry and laboratory medicine.

[13]  J. Matthews,et al.  Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab. , 2017, The Journal of allergy and clinical immunology.

[14]  A. Bathke,et al.  Exposure to Indoor Allergens in Different Residential Settings and Its Influence on IgE Sensitization in a Geographically Confined Austrian Cohort , 2017, PloS one.

[15]  N. Jarjour,et al.  Variability of blood eosinophil count as an asthma biomarker. , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[17]  E. Bateman,et al.  Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. , 2016, The Lancet. Respiratory medicine.

[18]  P. O'Byrne,et al.  Measuring Eosinophils to Make Treatment Decisions in Asthma. , 2016, Chest.

[19]  R. Tal-Singer,et al.  Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD , 2016, BMJ Open Respiratory Research.

[20]  Sadamu Okada,et al.  Current cigarette smoking is a reversible cause of elevated white blood cell count: Cross-sectional and longitudinal studies , 2016, Preventive medicine reports.

[21]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[22]  E. Schadt,et al.  Evaluation of direct-to-consumer low-volume lab tests in healthy adults. , 2016, The Journal of clinical investigation.

[23]  H. Ortega,et al.  Reproducibility of a Single Blood Eosinophil Measurement as a Biomarker in Severe Eosinophilic Asthma. , 2015, Annals of the American Thoracic Society.

[24]  E. Schapkaitz,et al.  Prolonged storage-induced changes in haematology parameters referred for testing , 2015 .

[25]  R. Maciuca,et al.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies , 2015, Thorax.

[26]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[27]  D. Khatry,et al.  High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. , 2014, The journal of allergy and clinical immunology. In practice.

[28]  Marika Egyed,et al.  Effects of Age, Season, Gender and Urban-Rural Status on Time-Activity: Canadian Human Activity Pattern Survey 2 (CHAPS 2) , 2014, International journal of environmental research and public health.

[29]  H. Ortega,et al.  Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. , 2013, Annals of the American Thoracic Society.

[30]  Ruksha Bhadresha Dupilumab in persistent asthma with elevated eosinophil levels , 2013, Thorax.

[31]  Stefan W Krause,et al.  Comparison of automated differential blood cell counts from Abbott Sapphire, Siemens Advia 120, Beckman Coulter DxH 800, and Sysmex XE-2100 in normal and pathologic samples. , 2013, American journal of clinical pathology.

[32]  S. Spector,et al.  Is a Single Blood Eosinophil Count a Reliable Marker for “Eosinophilic Asthma?” , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

[33]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[34]  N. Ismail,et al.  Do indoor environments influence asthma and asthma-related symptoms among adults in homes?: a review of the literature. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.

[35]  T. Turhan,et al.  Effects of Storage Conditions on Complete Blood Cell Count Parameters , 2011 .

[36]  C. Slingluff,et al.  Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function , 2011, Journal of Translational Medicine.

[37]  P. Belloni,et al.  Effects of storage conditions of human whole blood on the viability of lymphocytes , 2008, International journal of radiation biology.

[38]  C. Janson,et al.  Systemic and local eosinophil inflammation during the birch pollen season in allergic patients with predominant rhinitis or asthma , 2007, Clinical and molecular allergy : CMA.

[39]  M. Suliman,et al.  Seasonal Variation in Eosinophil Count in Normal Healthy Adult Females , 2004 .

[40]  J. Margolick,et al.  Effects of asthma on cell components in peripheral blood among smokers and non‐smokers , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[41]  A. Sutani,et al.  Theophylline Attenuates the Adhesion of Eosinophils to Endothelial Cells , 2003, International Archives of Allergy and Immunology.

[42]  H. Bessler,et al.  Relationship Between Temperature and Apoptosis of Human Peripheral Blood Mononuclear Cells , 2003, International journal of hematology.

[43]  P. Kuna,et al.  A randomized, double-blind trial of the effect of treatment with formoterol on clinical and inflammatory parameters of asthma in children. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[44]  B. Krebs,et al.  Diagnostic significance of blood eosinophilia in returning travelers. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Y. Okubo,et al.  Theophylline Inhibits TNF-α-Induced CD4 Expression on Human Eosinophils and CD4+ Eosinophil Migration , 2001, International Archives of Allergy and Immunology.

[46]  Original Research , 2000 .

[47]  R. Welliver,et al.  Eosinophilia at the Time of Respiratory Syncytial Virus Bronchiolitis Predicts Childhood Reactive Airway Disease , 2000, Pediatrics.